Q1 Earnings Forecast for BEAM Issued By HC Wainwright

Beam Therapeutics Inc. (NASDAQ:BEAM) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Beam Therapeutics in a research note issued on Monday, February 3rd. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.83) per share for the quarter. HC Wainwright has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS and FY2029 earnings at ($1.44) EPS.

A number of other brokerages have also weighed in on BEAM. Leerink Partners raised Beam Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $27.00 to $39.00 in a report on Wednesday, November 6th. Wedbush reiterated an “outperform” rating and set a $57.00 target price on shares of Beam Therapeutics in a research report on Monday, January 13th. Cantor Fitzgerald upgraded Beam Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, January 29th. Sanford C. Bernstein upgraded Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Finally, Scotiabank started coverage on Beam Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $24.00 price objective on the stock. Two analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Beam Therapeutics presently has a consensus rating of “Buy” and an average target price of $47.67.

Beam Therapeutics Stock Performance

Shares of BEAM stock opened at $25.59 on Tuesday. Beam Therapeutics has a fifty-two week low of $20.84 and a fifty-two week high of $49.50. The firm has a market capitalization of $2.12 billion, a P/E ratio of -14.54 and a beta of 1.92. The stock’s fifty day moving average is $26.50 and its two-hundred day moving average is $25.76.

Beam Therapeutics (NASDAQ:BEAM) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.01). Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The business had revenue of $14.30 million during the quarter, compared to the consensus estimate of $14.52 million. During the same quarter in the prior year, the firm posted ($1.22) EPS. The company’s revenue for the quarter was down 16.9% on a year-over-year basis.

Insider Transactions at Beam Therapeutics

In related news, President Giuseppe Ciaramella sold 51,110 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $26.36, for a total transaction of $1,347,259.60. Following the sale, the president now directly owns 109,150 shares in the company, valued at $2,877,194. This represents a 31.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John M. Evans sold 30,000 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the completion of the transaction, the chief executive officer now owns 908,659 shares in the company, valued at $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,351 shares of company stock valued at $2,180,387. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Beam Therapeutics

Several institutional investors have recently modified their holdings of BEAM. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Beam Therapeutics by 59.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company’s stock worth $87,044,000 after acquiring an additional 1,328,414 shares in the last quarter. State Street Corp boosted its stake in Beam Therapeutics by 12.5% during the third quarter. State Street Corp now owns 3,929,557 shares of the company’s stock valued at $96,274,000 after buying an additional 437,402 shares during the last quarter. Peregrine Investment Management Inc. bought a new stake in shares of Beam Therapeutics in the 4th quarter valued at approximately $3,932,000. Bellevue Group AG raised its holdings in shares of Beam Therapeutics by 7.1% in the third quarter. Bellevue Group AG now owns 1,518,121 shares of the company’s stock worth $37,194,000 after buying an additional 100,000 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Beam Therapeutics by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company’s stock worth $44,297,000 after purchasing an additional 78,102 shares during the period. 99.68% of the stock is currently owned by institutional investors.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.